ChemoCentryx Securities Litigation

Summary of the Action and Settlement

This website relates to a settled securities class action brought by investors alleging that ChemoCentryx and its former President and Chief Executive Officer, Dr. Thomas J. Schall (together, “Defendants”), violated the federal securities laws by making material misrepresentations during the Class Period regarding ChemoCentryx’s ADVOCATE study, the Company’s Phase 3 clinical trial of its vasculitis drug avacopan, and concerning the Company’s communications with the FDA related to the approval of avacopan.

Class Representative, Indiana Public Retirement System on behalf of itself and the Class, has settled the Action in exchange for a settlement payment of $69,000,000 in cash (the “Settlement Amount”). 

On October 29, 2026, the Court held a hearing to consider final approval of the Settlement and other matters. Following the hearing, the Court entered a Judgment Approving Class Action Settlement, as well as orders approving the Plan of Allocation and Lead Counsel’s motion for attorneys' fees and litigation expenses.

If you are a member of the Class, your rights will be affected and you may be eligible for a payment from the Settlement. The Class consists of:

All persons who purchased or otherwise acquired the common stock of ChemoCentryx, Inc. (“ChemoCentryx” or the “Company”) from November 26, 2019 through May 6, 2021, inclusive (the “Class Period”), and were damaged thereby.

Certain persons and entities are excluded from the Class by definition (see paragraph 28 of the Settlement Notice). Also excluded from the Class are persons and entities who excluded themselves from the Class pursuant to the Class Notice and did not opt back into the Class.

Please read the Settlement Notice to fully understand your rights. Copies of the Settlement Notice and Claim Form can be found in the menu at the top of this page.

The deadline to submit a Claim Form to be eligible to participate in the Settlement is October 1, 2026.  Payments to eligible claimants will be made only after the completion of all claims processing. Please be patient, as this process will take some time to complete.